<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04848623</url>
  </required_header>
  <id_info>
    <org_study_id>CoLive Voice</org_study_id>
    <nct_id>NCT04848623</nct_id>
  </id_info>
  <brief_title>Identification of Vocal Biomarkers to Monitor the Health of People With a Chronic Disease</brief_title>
  <acronym>CoLive Voice</acronym>
  <official_title>Identification of Vocal Biomarkers to Monitor the Health of People With a Chronic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luxembourg Institute of Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luxembourg Institute of Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CoLive Voice research project aims to identify vocal biomarkers of severe conditions and&#xD;
      frequent health symptoms. The project is based on digital technologies and statistical&#xD;
      algorithms. This is an international anonymous survey where vocal recordings are collected&#xD;
      simultaneously with large validated clinical and epidemiological data, in the context of&#xD;
      various chronic diseases or frequent health symptoms in the general population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the objective of using vocal biomarkers for diagnosis, risk prediction/stratification&#xD;
      and remote monitoring of various clinical outcomes and symptoms, there is a major need to&#xD;
      develop surveys where audio data and clinical, epidemiological and patient-reported outcomes&#xD;
      data are collected simultaneously.&#xD;
&#xD;
      The objectives of CoLive Voice are:&#xD;
&#xD;
        -  To launch an international anonymized survey where vocal recordings are associated with&#xD;
           large validated clinical and epidemiological data, in the context of various chronic&#xD;
           diseases or frequent health symptoms in the general population&#xD;
&#xD;
        -  To extract audio features and train supervised machine learning models to identify key&#xD;
           candidate vocal biomarkers of the aforementioned chronic conditions or related symptoms.&#xD;
&#xD;
      Participants will be recruited online and will complete the survey using a web application.&#xD;
&#xD;
      They will first answer a detailed questionnaire on their health status and then do 5&#xD;
      different voice records:&#xD;
&#xD;
        1. read a 30 sec prespecified text (from the Human Rights Declaration),&#xD;
&#xD;
        2. sustain voicing the vowel /aaaaaa/ as long and as steady as they can at a comfortable&#xD;
           loudness&#xD;
&#xD;
        3. cough 3 times&#xD;
&#xD;
        4. breath in and out deeply 3 times&#xD;
&#xD;
        5. Count from 1 to 20 at a normal speed&#xD;
&#xD;
      Vocal records will be pre-processed and converted into features, meaning the most dominating&#xD;
      and discriminating characteristics of a vocal signal. Following the selection of features,&#xD;
      machine or deep learning algorithms will be trained to automatically predict or classify the&#xD;
      clinical, medical or epidemiological outcomes of interest, from vocal features alone or in&#xD;
      combination with other health-related data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2031</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Stress</measure>
    <time_frame>At baseline</time_frame>
    <description>Patient reported outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>At baseline</time_frame>
    <description>Patient reported outcome using the fatigue severity scale (FSS). Minimum value =1, max value = 7 ; 7 is the highest level of fatigue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertension</measure>
    <time_frame>At baseline</time_frame>
    <description>Patient reported outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes</measure>
    <time_frame>At baseline</time_frame>
    <description>Patient reported outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Migraine</measure>
    <time_frame>At baseline</time_frame>
    <description>Patient reported outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Covid-19</measure>
    <time_frame>At baseline</time_frame>
    <description>Patient reported outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall pain</measure>
    <time_frame>At baseline</time_frame>
    <description>Patient reported outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory problems</measure>
    <time_frame>At baseline</time_frame>
    <description>Patient reported outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of quality of life</measure>
    <time_frame>At baseline</time_frame>
    <description>Patient reported outcome</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50000</enrollment>
  <condition>Chronic Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult and adolescent above 15 years, regardless of their health status and their residence&#xD;
        country.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adolescents and adults &gt; 15 years&#xD;
&#xD;
          -  With or without health conditions&#xD;
&#xD;
          -  From all countries&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children &lt; 15 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guy Fagherazzi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LIH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aurelie Fischer, MSc</last_name>
    <phone>00352621328591</phone>
    <email>aurelie.fischer@lih.lu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Luxembourg Institute of Health</name>
      <address>
        <city>Luxembourg</city>
        <country>Luxembourg</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurelie Fischer, MS</last_name>
      <phone>00352 621328591</phone>
      <email>colivevoice@lih.lu</email>
    </contact>
    <investigator>
      <last_name>Guy Fagherazzi, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Luxembourg</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 12, 2021</study_first_submitted>
  <study_first_submitted_qc>April 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vocal biomarker</keyword>
  <keyword>digital biomarker</keyword>
  <keyword>digital health</keyword>
  <keyword>artificial intelligence</keyword>
  <keyword>telemonitoring</keyword>
  <keyword>medical devices</keyword>
  <keyword>precision health digital biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

